Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2010 1
2012 2
2013 3
2014 4
2015 1
2016 2
2017 1
2018 1
2019 3
2020 6
2021 6
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Jani AB, et al. J Urol. 2023 Aug;210(2):299-311. doi: 10.1097/JU.0000000000003493. Epub 2023 Apr 26. J Urol. 2023. PMID: 37126069
Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study.
Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: miller mp. Cancer Biother Radiopharm. 2022 Apr;37(3):205-213. doi: 10.1089/cbr.2021.0322. Epub 2021 Dec 28. Cancer Biother Radiopharm. 2022. PMID: 34962139 Clinical Trial.
Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer.
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: miller mp. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3723-3731. doi: 10.1007/s00259-021-05346-8. Epub 2021 Apr 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33846844 Free PMC article.
chTOG is a conserved mitotic error correction factor.
Herman JA, Miller MP, Biggins S. Herman JA, et al. Among authors: miller mp. Elife. 2020 Dec 30;9:e61773. doi: 10.7554/eLife.61773. Elife. 2020. PMID: 33377866 Free PMC article.
34 results